Seres Therapeutics, Inc. (MCRB) NASDAQ

13.99

-0.27(-1.89%)

Updated at August 01 04:00PM

Currency In USD

Seres Therapeutics, Inc.

Address

200 Sidney Street

Cambridge, MA 02139

United States of America

Phone

617 945 9626

Sector

Healthcare

Industry

Biotechnology

Employees

103

First IPO Date

June 26, 2015

Key Executives

NameTitlePayYear Born
Mr. Eric D. Shaff M.B.A.President, Chief Executive Officer & Director1.11M1976
Dr. Teresa L. Young Ph.D., R.Ph.Executive Vice President and Chief Commercial & Strategy Officer606,3271967
Dr. Matthew R. Henn Ph.D.Executive Vice President & Chief Scientific Officer643,8281975
Mr. Thomas J. DesRosier Esq., J.D.Chief Legal Officer, Executive Vice President & Secretary707,1421955
Ms. Kelly BradySenior Vice President of Clinical Development0N/A
Ms. Caroline HensleyAssistant General Counsel0N/A
Dr. Dennis M. Walling M.D.Senior Vice President of Clinical Development & Head of Clinical Research0N/A
Ms. Marella Thorell CPAExecutive Vice President & Chief Financial Officer01967
Mr. Chris McChalicherSenior Vice President of Manufacturing, Quality, and Process Development0N/A
Ms. Ann KurowskiSenior Vice President of Regulatory Affairs0N/A

Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.